ProShare Advisors LLC increased its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA – free report ) by 14.8% during the first quarter, according to the latest filing with the Securities and Exchange Commission. The institutional investor acquired an additional 4,210 shares during the period, bringing its holdings to 32,690 shares of the company’s stock. ProShare Advisors LLC’s holdings in Sana Biotechnology were worth $327,000 as of the latest filing with the Securities and Exchange Commission.
Other hedge funds also increased or decreased their holdings of the company’s stock. Victory Capital Management acquired a new stake in Sana Biotechnology in the fourth quarter, valued at approximately $54,000. Cantonal Bank of Zurich increased its holdings in Sana Biotechnology by 42.1% in the fourth quarter. Cantonal Bank of Zurich now holds 16,257 shares of the company’s stock, valued at $66,000, after acquiring an additional 4,815 shares in the last quarter. Simplex Trading LLC increased its holdings in Sana Biotechnology by 31.3% in the fourth quarter. Simplex Trading LLC now holds 18,080 shares of the company’s stock, valued at $73,000, after acquiring an additional 4,313 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Sana Biotechnology by 351.8% in the fourth quarter. China Universal Asset Management Co., Ltd. now holds 22,800 shares of the company’s stock, valued at $93,000, after purchasing an additional 17,753 shares in the last quarter. Finally, E Fund Management Co., Ltd. increased its holdings in Sana Biotechnology by 40.0% in the fourth quarter. E Fund Management Co., Ltd. now holds 23,361 shares of the company’s stock, valued at $95,000, after purchasing an additional 6,673 shares in the last quarter. 88.23% of the stock is owned by institutional investors.
Analyst upgrades and downgrades
Several research analysts have recently issued reports on the stock. Rodman & Renshaw initiated coverage on shares of Sana Biotechnology in a report on Wednesday, June 26th. The firm issued a “buy” rating and a $16.00 price target for the company. HC Wainwright reaffirmed their “buy” rating and set a $12.00 price target on shares of Sana Biotechnology in a report on Thursday, May 9th. One analyst has given the company a hold rating, and four have assigned a buy rating to the company. According to MarketBeat data, Sana Biotechnology has a consensus rating of a “moderate buy” with an average price target of $12.75.
Get the latest stock analysis for Sana Biotechnology
Sana Biotechnology Stock Performance
Sana Biotechnology shares opened trading at $6.40 on Friday. The company has a market cap of $1.42 billion, a price-to-earnings ratio of -4.18 and a beta of 1.45. Sana Biotechnology has a 52-week low of $2.74 and a high of $12.00. The company’s 50-day moving average price is $6.44 and its 200-day moving average price is $7.57.
Sana Biotechnology, Inc. (NASDAQ:SANA – Get free report ) last announced its earnings results on Wednesday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). Equity research analysts overall expect that Sana Biotechnology, Inc. will post -1.15 EPS for the current fiscal year.
Sana Biotechnology Company Profile
(Free report)
Sana Biotechnology, Inc. is a biotechnology company focused on the use of genetically engineered cells as medicines. The company is developing in vitro and in vivo cell engineering platforms for a variety of therapeutic areas of unmet therapeutic need, including oncology, diabetes, central nervous system disorders and B-cell mediated autoimmunity.
References
Get Sana Biotechnology News and Ratings Daily – Enter your email address below to receive a concise summary of the latest news and analyst ratings on Sana Biotechnology and related companies every day with MarketBeat.com’s free email newsletter.
